Welcome to our dedicated page for DALRADA FINCL news (Ticker: DFCO), a resource for investors and traders seeking the latest updates and insights on DALRADA FINCL stock.
Dalrada Financial Corporation, through its subsidiaries, provides various products and services in the manufacturing, engineering, and healthcare sectors worldwide. The company offers low-carbon heating and cooling systems, visual inspection kits for detecting cervical cancer, and software solutions in test engineering, accessibility engineering, and more. Additionally, it provides cleaning solutions with electrostatic machines for various facilities. Formerly known as Imaging Technologies Corporation, Dalrada Financial Corporation was incorporated in 1982 and is headquartered in Escondido, California.
The company, under the leadership of CEO Brian Bonar, focuses on driving innovation in the Clean Energy and Health Care sectors. Its segments include Dalrada Climate Technology and Genefic Specialty Pharmacy, offering advanced heat pump technology and end-to-end prescription services, respectively. With a commitment to sustainability and cutting-edge solutions, Dalrada Financial Corporation aims to deliver value to its shareholders.
Dalrada Financial (OTCQB: DFCO) announced that its healthcare subsidiary, Genefic, has acquired IV Services, , a leading pharmaceutical and infusion management company. This acquisition strengthens Genefic’s market position by expanding its sales and operational footprint, increasing top-line revenue, and enhancing patient care capabilities. The acquisition is non-dilutive to shareholders and allows Genefic to enter the $42 billion global infusion pharmacy management market, which is expected to grow to $70 billion by 2030. Genefic gains new regional presence in Louisiana and Mississippi, complementing its existing operations in several other U.S. states.
Dalrada Financial (OTCQB: DFCO) filed a Form 10-Q for Q3 2024, revealing a revenue of $10.3 million, driven primarily by its pharmaceutical subsidiary, Genefic Specialty Pharmacy. Genefic accounted for $8.6 million, an 80% increase from Q3 2023 and a 95.5% rise from the previous quarter. The company also converted $13.3 million of affiliate debt to Series I preferred shares, reducing net losses to $2.9 million, the lowest since 2021. CEO Brian Bonar emphasized ongoing efforts to clear debt and reduce expenditures, with a net equity of $8.8 million. Dalrada anticipates continued growth in Q4 and a year-over-year revenue increase by the end of fiscal 2024.
FAQ
What is the current stock price of DALRADA FINCL (DFCO)?
What is the market cap of DALRADA FINCL (DFCO)?
What products and services does Dalrada Financial Corporation offer?
When was Dalrada Financial Corporation incorporated?
Where is Dalrada Financial Corporation headquartered?
Who is the CEO of Dalrada Financial Corporation?
What are the core segments of Dalrada Financial Corporation?
What is the focus of Dalrada Financial Corporation?
What is the mission of Dalrada Financial Corporation?
